People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sojournix, Inc. | — | Pharmaceuticals | Series C | $71.4M | $1.5B | 2018 |
Peter S. Lanciano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter S. Lanciano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter S. Kolchinsky | 1 | 2 |
| Peter L. Kolchinsky | 1 | 2 |
| Daniel S. Grau | 1 | 2 |
| Martin S. Freed | 1 | 1 |
| Aaron S. Davis | 1 | 1 |
| Martin L. Freed | 1 | 1 |
| Aaron L. Davis | 1 | 1 |
| Peter L. Lanciano | 1 | 1 |
| Scott L. Rakestraw | 1 | 1 |
| Scott S. Rakestraw | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.